HDAC9 and cancer: It has recently been reported that KRAS mutant can promote Rad51 expression to increase the chemotherapy resistance of cancer cells, while inhibiting HDAC can down-regulate Rad51 to counteract Rad51-mediated resistance of cancer cells [14, 15].